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1. Introduction 
Immunoassays are useful laboratory methods for clinical and forensic toxicology 
diagnostics. The methods are fast, sensitive, accurate and let determine poisons 
concentrations in different kinds of biological fluids. There are blood and urine or 
alternative: saliva, sweat and hair. The choice of the sample depends on the purpose of 
analysis. In acute poisoning the blood or serum poison concentration is important, but when 
the diagnosis is made more than 24 h post-ingestion, the urine sample should be collected 
and analyzed. The urine toxicology analysis let confirm the poison’s ingestion. Alternative 
samples are more and more common, but they are used usually in forensic toxicology, in 
medical toxicology the results of hair or sweat determination are useful in the history of 
drugs overdosing or abusing research. Toxicological diagnostics is consequence, enables to 
make distinction if observed patient’s symptoms are correlated to poisoning or other 
reasons. Fast quantitative measurement is important for poisoning confirmation, prognosis 
and decisions about specific treatment. All emergency rooms and poisoning treatment 
centers should have full access to such diagnostics. The most important immunoassay 
determinations are: the most often (e.g. alcohol, benzodiazepines, drugs of abuse) and the 
decision making ones (e.g. acetaminophen, phenobarbital, digoxin, amanitines).  
The attributes of toxicological tests differ depending on the purpose of determination. When 
poisoning cause is to be identified – specificity is most important, to distinguish the poison 
from other exogenous or endogenous substances. When screening is made to check patient’s 
abstinence – sensitivity of the test is most important. The sensitivity is usually set as a cut-off 
value – the concentration, above which the result is reported as positive. When test is used 
for therapeutic drug monitoring (TDM) purpose – test precision is most important, to follow 
changes of drug concentration in a narrow, therapeutic range. The most important points of 
toxicological tests are presented in Table 1. 
The immunoassay method should be selected after consulting it’s advantages and 
disadvantages. The choice of immunoassays is wide. There are simple qualitative cassettes 
or bar-tests and more accurate apparatus for semi-quantitative and quantitative 
measurements. They differ with sensitivity, cut-off values, kind of tested sample, result 
interpretation. All of them have some limitations and sometimes need confirmation by 
reference method.  
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Test Indication 
Preselection or 
Suspicion 
Probability 
Test 
Attribute 
Example 
Poisoning 
Diagnostics 
Finding a 
Poisoning 
Cause 
No Moderate Specificity 
Looking for 
a poison 
Screening Checking Yes Low Sensitivity 
Abstinence 
Checking 
Therapeutic 
Drug 
Monitoring 
Monitoring 
Concentration 
Changes 
Yes High Precision Therapy 
Table 1. Toxicological tests and their attributes 
Aspects concerned with pre-analytical, analytical and post-analytical phases are important in a 
diagnosis process. The laboratory staff must know all immunoassay limitations and watch out 
for false results. The immunoassay methods became commonplace and toxicology diagnostics 
is performed in laboratories, where there are no reference and confirmation methods. Low cost 
and easy-automation encourage to start toxicology determinations in many clinical 
laboratories. Sometimes there are no toxicology specialists in the laboratories. Sometimes 
results interpretation cannot be performed properly without confirmation.  
There are some analytical problems connected with toxicology diagnosis, especially when it 
is performed by immunoassay. One of the most important problem is result verification and 
creation result report. Immunoassay is not quite reliable. Analyst is responsible for false 
results, even when the misinterpretation is caused by limitation of immunoassay method. 
Some proceedings should be considered, for example, what to do when the result is 
doubtful and how to perform confirmation. 
Most toxicology laboratories have access to reference methods and can confirm uncertain 
results. Analyst performing toxicology immunoassay in general laboratory should know all 
limitations of used method, know how to prepare reports, when to confirm results, how to 
store and transport sample for confirmation.  
2. Immunoassays in toxicology 
Acute intoxicated patient should be diagnosed as soon as possible. The biological samples 
are usually collected from poisoned patients in emergency rooms or in toxicology 
department. The collection time should be noted, because it influences the result 
interpretation. Medical laboratories usually use automatic immunoanalysers with methods: 
enzyme multiplied immunoassay technique (EMIT), fluorescent polarization immunoassay 
(FPIA), microparticle enzyme immunoassay (MEIA), cloned enzyme donor immunoassay 
(CEDIA), kinetic interaction of microparticles in solution (KIMS). They are useful for blood 
or serum therapeutic drug monitoring. They are also useful for serum and urine 
determinations of ethanol, medicines, drugs of abuse and other toxins. Other common 
immunoassays are cassette or strip rapid tests. Such tests are dedicated for urine or saliva 
determinations of drugs of abuse (amphetamines, barbiturates, benzodiazepines, 
cannabnoids, cocaine, ecstasy, methadone, opiates, phencyclidine, tricyclic antidepressants). 
Their sensitivity is usually set on a level appropriate for workers control or abstinence 
control of patients participating in drug substitution treatment. 
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Immunoassay methods do not enable to determine all poisons, drugs or biomarkers of 
exposition. In order to measure all of them, other methods are needed. There are 
spectrometry methods: ultraviolet/visible spectrometry, atomic absorption spectrometry 
(AAS); chromatography methods: thin layer chromatography (TLC), gas chromatography 
(GC), high performance liquid chromatography (HPLC) and chemical tests. They are 
complements to immunoassays, and they are used for confirmation positive immunoassay 
results. Examples of methods and determined substances in clinical and forensic toxicology 
are showed in Table 2. 
 
Immunoassay Chromatography Spectrometry 
RIA 
CEDIA  
EIA / EMIT 
ELISA 
FIA / FPIA, DELFIA 
KIMS 
MEIA 
POC (casette/strip 
rapid test) 
TLC, HPTLC 
GC 
HPLC 
GC/MS 
LC/MS 
Colorimetry 
Spectrophotometry UV 
Spectrophotometry VIS 
Spectrophotometry IR 
AAS 
AES 
Amanitine 
Ethanol 
Drugs of abuse 
Therapeutic Drug 
Monitoring 
Ethanol and other alcohols 
(Methanol, Ethylene Glycol, 
Izopropanol) 
Solvents 
Drugs of abuse 
Designer Drugs 
Medicines and metabolites 
Natural Toxins (e.g. Atropine, 
Scopolamine) 
Pesticides 
Solvents 
Alcohols 
Medicines 
Pesticides 
Metals and Metalloids 
Biomarkers of exposition to 
chemical compounds 
(Carboxyhemoglobine COHb, 
Methemoglobine MetHb, Blood 
Acetycholinoesteraze activity AChE) 
RIA – Radioimmunoassay, CEDIA – Cloned Enzyme Donor Immunoassay, EIA / EMIT – Enzyme-
Immunoassay / Enzyme Multiplied Immunoassay Technique, ELISA – Enzyme-Linked 
Immunosorbent Assay, FIA / FPIA – Fluorescence Immunoassay / Fluorescence Polarization 
Immunoassay, KIMS – Kinetic Interaction of Microparticles in Solution, MEIA – Microparticle Enzyme 
Immunoassay, POC – Point of Care 
TLC, HPTLC – Thin Layer Chromatography, GC – Gas Chromatography, HPLC – High Performance 
Liquid Chromatography, GC/MS – Gas Chromatography with Mass Spectrometry, LC/MS – Liquid 
Chromatography with Mass Spectrometry 
Table 2. Examples of laboratory methods and determined substances in toxicology 
3. Pre-analytical aspects of immunoassay in toxicology 
3.1 Collecting samples for immunoassay in toxicology diagnostics 
Homogenous methods, in which a sample is added to mixture of reagents, immunological 
reaction goes between analyte and antibody in homogenous solution, (e.g. EMIT, FPIA, 
CEDIA, KIMS). They are useful for diagnostics of acute poisoned patients performed in 
blood, serum and urine. Heterogeneous methods, in which a sample is added to reaction 
www.intechopen.com
 
Trends in Immunolabelled and Related Techniques 
 
70
vessels with antibodies immobilized on the bottom (e.g. ELISA) can be used for forensic 
determinations of drugs in previous mentioned samples and in alternative samples (hair, 
sweat, saliva) after sample preparation. Rapid tests are usually dedicated for urine or saliva 
determinations. Drugs of abuse and some medicines are measured qualitative or semi-
quantitative; TDM needs quantitative determinations (Table 3). 
 
Qualitative tests  
(cassettes, strips) 
Semi-quantitative tests 
 
Quantitative tests 
 
Urine or Saliva Urine or Serum Serum or Whole Blood 
Acetaminophen 
Amphetamine 
Barbiturates 
Benzodiazepines 
Buprenorphine 
Cannabinoids (THC) 
Cocaine 
EDDP (methadone metabolite)
Ecstasy (MDMA) 
Ethanol 
LSD 
Methadone 
Metamphetamine 
Morphine 
Opiates 
Phencyclidine (PCP) 
Tramal 
Tricyclic antidepressants 
Amanitine 
Amphetamine/Metamphetam
ine 
Barbiturates 
Benzodiazepines 
Cannabinoids (THC) 
Cocaine 
Ecstasy (MDMA) 
LSD 
Tricyclic antidepressants 
Acetaminophen 
Amikacine 
Carbamazepine 
Cyclosporine 
Digoxin 
Ethanol 
Gentamycine 
Lidocaine 
Phenobarbital 
Phenytoine 
Salicylates 
Teophylline 
Tobramycine 
Tricyclic antidepressants 
Valproic Acid 
Vancomycine 
Table 3. Some substances determined by qualitative, semi-quantitative and quantitative 
immunoassays in different biological samples 
Each kind of sample has a different detection time. The pharmacokinetics parameters of 
analyzed substances also influence the results interpretation. The detection window is the 
period of time when the substance can be detected in the sample. Blood, serum and saliva 
have a narrow detection window (1-24 h). Urine has a wider one (2-7 days) and hair has the 
widest one (several months). The detection window depends on the kind of collected 
sample, the kind of determined drug and the frequency of the drug ingestion (Table 4). 
Sometimes the detection time is prolonged, for example marihuana metabolites can be 
detected in urine for one to three weeks, depending on the size and frequency of marihuana 
ingestion. When the sample is collected in time out of the detection window (too early or too 
late) the result is negative in spite of visible patients symptoms connected with drug 
ingestion. 
Collecting samples for therapeutic drug monitoring is different. Before starting TDM, the 
steady state of drug should be achieved. Depending on drug biological half time, the steady 
state is achieved in time from several hours to several days (Table 11). 
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Substance 
Detection window 
Occasionally Chronic 
Amphetamine derivatives 48 h Up to 7 days 
Barbiturates 
Short acting: 24 h 
Long acting: 2-3 weeks 
Benzodiazepines 
Short acting: 24 h 
Long acting : 3 days 
Cocaine 2-3 days Up to 7 days 
Methadone 2-3 days 1-2 weeks 
Opiates 2-3 days Up to 7 days 
THC (Marijuana) 
once: to 4 days 
occasionally: to 10 days 
passive exposition: not detected
4-6 weeks 
Table 4. Urine detection window for drugs of abuse 
The assay tests and reagents are dedicated for different kinds of samples. Every kind of 
sample contains specific background and it is not allowed to analyze serum using urine or 
saliva tests and vice versa.  
The choice of the kind of sample depends on the purpose of determination. Blood and 
serum samples contain ingested substances. Urine samples contain mainly their metabolites. 
When acute poisoning diagnostics is made, the blood or serum samples are chosen. The 
blood and serum concentrations correlate with ingested dose of drug, correlate with 
poisoning symptoms and sometimes, give information about predictable poisoning effects. 
The diagnosis is useful when the physician wants to make decision about specific treatment 
with antidote or extracorporeal elimination. But when the time from drug ingestion to 
diagnosis is too long (longer than five biological halftimes) collecting the blood for 
poisoning diagnosis can be useless. The blood or serum results will be negative and urine 
sample should be collected. The urine concentration does not correlate the poisoning 
symptoms and does not have prediction value. But the urine presence of drug and it’s 
metabolites confirms the patient has ingested the drug and the observed symptoms are 
connected with the poisoning.  
Urine samples are collected when abstinence of patients and workers is analyzed. When the 
abstinence is checked, the urine adulteration or cheating is possible. Table 5 presents some 
possible urine cheating and ways of their recognition. Probably there are not all possible 
ways of cheating samples, that’s why the best way of avoiding cheating is control the 
patients during collecting urine samples. Despite some disadvantages, the urine is quite 
good kind of sample for abstinence control. Urine is collected non-invasive and has a wide 
detection window. The most important differences between urine and blood (serum) 
samples are showed in Table 6.  
Tests for urine determination of drugs of abuse and medicines have sensitivity on different 
levels. Laboratories should have tests with different cut-off levels. Cut-off levels in acute 
poisoning diagnosis should be the lowest, in patients of substitution therapy can be higher, 
in workers control can be the highest. High cut-off level means lower sensitivity and 
reduction of questionable or “false positive” results (caused by substances present in food or 
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supplements). Cut-off concentrations dedicated for qualitative urine and saliva drugs of 
abuse determination are showed in Table 7 and Table 8. 
 
Adulteration Recognition 
Dilution Evaluation of urine colour, temperature, creatinine 
concentration, density 
Glutaric alhehyde  Urine strip test  
Nitrates Urine adulteration strip test 
Soup, Bleach etc. Evaluation of pH, look (foam), colour, fragrance 
Acid, Alkali Evaluation of pH, Urine adulteration strip test 
Peroxides Urine adulteration strip test 
Vitamines, medicines Chromatography analysis 
Table 5. Urine adulteration and it’s recognition  
 
 Urine Blood (serum) 
Detection window Wide (days, weeks) Narrow (hours) 
Concentration levels High Low 
Analytes Metabolites and toxins Toxins 
Correlation to intoxication symptoms No Yes 
Cut off values High Low 
pH influence Yes Yes 
Adulteration risk Yes No 
Cost Low High 
Table 6. Differences between urine and blood (serum) samples 
 
Analyte cut-off concentration ng/ml 
Amphetamine 1000, 500 
Barbiturates 300 
Benzodiazepines 200, 300 
Cannabinoids (THC) 50 
Cocaine 300 
Extasy (MDMA) 1000, 500 
Methadone 300 
Methamphetamine 1000, 500 
Opiates 300, 2000 
Phencyclidyne (PCP) 25 
Tricyclic antidepressants 1000 
Table 7. Cut-off concentrations dedicated for urine drugs of abuse determination by 
immunoassay 
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Analyte cut-off concentration ng/ml detection window 
Amphetamine 50 10 min – 72 h 
Cannabinoids (THC) 12 10 min – 72 h 
Cocaine 20 10 min – 24 h 
Methamphetamine 50 10 min – 72 h 
Opiates 40 10 min – 72 h 
Phencyclidyne (PCP) 10 10 min – 72 h 
Table 8. Cut-off concentrations and detection windows for saliva drugs of abuse 
determination by immunoassay 
4. Analytical aspects of immunoassay in toxicology 
Immunoassay reagents are usually dedicated to closed auto-sampler systems, in which 
analyst’s errors are minimized. Anyway, some aspects are important, and no automatic 
system can solve them. For example in situation of acute poisoned patient, when the 
measured poison concentration is out of calibration range. The necessity of sample dilution 
cause some manual manipulation. The diluent is usually distilled water or saline. 
Sometimes reagent kit contains a special diluent dedicated for a sample and analyte.  
Cassette or strip immunotests are performed manually. Cassette is a device in which a 
sample is dropped into a special reservoir, strip is usually drown into liquid sample. 
Usually they are simple to do, but some errors are possible when the laboratory staff is 
unqualified. Too much or too little sample amount used for the test, inadequate reading 
time and invalid reading are possible. The factors can cause false test result. When the 
laboratory staff is experienced the error factors are reduced. Both cassette and strip contain a 
control bar placed in a distance from reading area. The control bar is getting colour when 
sample reaches the control area. It shows if the test is performed correctly. Laboratory staff 
must realize, the control bar is not a quality control. Quality assurance is realized only when 
controls samples (with known concentrations of measured substances) are analyzed.  
4.1 Quality controls in immunoassay in toxicology 
All laboratories are obliged to keep internal and external quality control (EQC) systems. They 
are dedicated for the analyzed kind of sample (biological matrix), and the proper levels of 
analytes concentrations. Usually three levels of internal quality controls (low, medium and 
high) are performed. They let asses precision of the method on tree controlled levels. Precision 
is graphical illustrated as control charts (for example Levey-Jennings charts). 
External quality controls let verify accuracy of the method. Laboratories participating in 
EQC programme get certificate of quality assurance which is necessary in laboratory 
accreditation procedure. 
4.2 Immunoassay sensitivity and specificity 
Sensitivity reflects the lowest concentration giving positive result. Some immunoassays are 
useful for determination of a group of substances, for example benzodiazepines, barbiturates, 
amphetamines or opiates. The substances derivatives influence the results depending on their 
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sensitivity. Some of the derivatives have higher, and some have lower sensitivity, so they 
produce different results. For example 3,4-methylendioxymethamphetamine (MDMA) usually 
is not detected in immunoassays dedicated to amphetamines measurements because MDMA 
cross react when it’s concentration in sample is nine times higher than amphetamine. We 
name the result “false negative”. 
Specificity is a property enabling to distinguish measured drug from other compounds. The 
drug metabolites, it’s derivatives and other unknown compounds can interact the 
immunoassay reagents and produce elevated or “false positive” results. For example in 
therapeutic drug monitoring the physician is interested in the blood or serum concentration 
of the drug ingested by patient. But the result usually is elevated by the drug metabolites. 
Another example of interfering substance is codeine, which cross react in morphine and 
opiates tests and produce positive results. We name them “false positive”. The interfering 
substances can be medicines, supplements, drug components or endogenous compounds 
(for example DLIS - digoxin like immunoreactive substances). Other examples of 
interferences in immunoassays are showed in Table 9.  
 
Analyzed compound or group Interfering substance 
Amphetamines Fenfluramine, Ephedrine 
Opiates (Morphine) Codeine 
Benzodiazepines Oxaprozin 
Cannabinoids Niflumic Acid 
Tricyclic Antidepressants Carbamazepine, Phenotiazines 
Digoxin DLIS 
Table 9. Examples of interferences in immunoassay 
The positive results should be confirmed by specific chromatography methods. The 
confirmation is obligatory in forensic toxicology. Forensic toxicology use immunoassays as 
initial screening analysis; all the positive results must be confirmed by chromatography 
methods coupled with mass detection (GC/MS, LC/MS). The confirmation is optional in 
clinical toxicology. Most clinical laboratories do not have an access to time consuming and 
expensive chromatography methods.  
5. Comparison of immunoassay and chromatography methods in some 
toxicology diagnostics 
5.1 Alcohol determination 
Alcohol is the most often abused drug and one of the most often cause of hospitalization in 
toxicology departments. Immunological methods became common in measurement of 
ethanol about 20 years ago. The methods are automated and reliable, they replaced manual 
Widmark’s method and are comparable to gas chromatography and breathanalysis. Their 
sensitivity is usually less than 0,05 g/l. Interferences of non consumable alcohols (e.g. 
methanol, ethylene glycol, isopropanol) is insignificant (less than 1 %). The only interfering 
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alcohol can be n-butanol (18,5 %), but n-butanol is rather not present in any home products, 
and intoxication with the compound is hardly likely.  
Correlation of alcohol results obtained by immunoassay and gas chromatography is 
acceptable. The only disadvantage of alcohol immunoassay test is a relatively narrow 
linearity range. In heavy drinkers blood the alcohol concentration can be higher than 3 g/l. 
When the linearity range is not wide enough, the sample dilution is needed.  
The attention should be drown to collection of blood sample for alcohol measurement. 
Blood can be contaminated when alcohol solution is used during draw blood.  
Interpretation of blood and serum alcohol concentration should mind that serum alcohol 
concentration is higher than whole blood alcohol concentration. The difference is correlated 
to the concentration and can be calculated: blood alcohol concentration = serum alcohol 
concentration / 1,2. When serum ethanol concentration is not higher than 1 g/l, the 
difference is up to 0,16 g/l. Higher ethanol concentration implicate higher difference 
between serum and blood concentration. 
5.2 Benzodiazepines determination 
Benzodiazepines are often abused drugs. They are also used as date-rape drugs. The 
immunological methods measure concentration of benzodiazepines as a group of 
substances with basic shell of benzodiazepines rings. There are several known 
benzodiazepines and their metabolites that influence the immunoassay dedicated to this 
group of drugs. The interpretation of serum or urine benzodiazepines concentration result 
is not easy. They have different doses, applications, acting times and therapeutic ranges. 
Their affinities to immunoassay reagent are also different. In addition the immunoassay 
result is correlated to the sum of ingested benzodiazepines and their metabolites in 
biological sample. Some drugs (e.g. lorazepam, chlordiazepoxide) cross react with low 
efficiency. Other cross react with high efficiency (e.g. diazepam, oxazepam, alprazolam). 
The comparison of EMIT and HPLC showed, that benzodiazepines can produce results 
higher (alprazolam, diazepam), equel (nordiazepam) and lower (estazolam) than real 
drug concentration. 
5.3 Carbamazepine determination 
Carbamazepine is a common anticonvulsive drug. There are indications to measure 
carbamazepine concentration during therapy. Therapeutic drug monitoring make therapy 
safe, reduce risk of too low or too high dosage, and side effects. Immunoassay enables to 
control the blood carbamazepine concentration.  
Comparison of EMIT and HPLC method showed differences in measured carbamazepine 
concentrations. EMIT results reflects sum of carbamazepine and it’s metabolites 
concentrations. HPLC is a method enabling to separate carbamazepine and it’s metabolites 
and quantify them separately.  
The carbamazepine results interpretation should provide for the method. Anyway 
immunoassay is a good method for therapeutic drug monitoring, when the blood samples 
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are collected in a drug stationary phase and minimum drug concentration is measured 
(blood sample is collected before ingestion a dose).  
Carbamazepine determination by immunoassay in acute poisoning does not let distinguish 
intoxication phase. Carbamazepine metabolites concentrations are low in absorption phase, 
later the equilibrium between drug and their metabolites concentration is established. 
Finally, in the elimination phase, carbamazepine metabolites concentrations are the highest. 
Immunoassays do not let demonstrate the changes, the result just reflects the sum of drug 
and it’s metabolites.  
5.4 Tricyclic antidepressants determination 
Tricyclic antidepressants (TCA) are the group of drugs used in psychiatric treatment. They 
are often abused by patients addicted to drugs of abuse. The drugs are toxic in elevated 
doses, but the correlation between serum TCA concentration and poisoning symptoms is 
rather weak. The serum TCA concentrations can be referred to ingested dose when analyst 
knows the name of drug. Table 11 shows variations among TCA therapeutic ranges.  
The TCA concentration measured by immunoassay can be influenced by other substances. 
For example carbamazepine and some phenotiazines are common medicines elevating TCA 
immunoassay results (Table 9). 
 
Substance Volume of distribution Elimination half-life 
Amphetamines 3-33 L/kg 10-30 h 
Excretion pH dependent 
Barbiturates (Phenobarbital) 0,7-1,5 L/kg 48-288 h 
Benzodiazepines 
(Diazepam) 
0,5-5 L/kg 20-40 h 
Cannabis 10 L/kg 20-30 h 
Cocaine 1,2-1,9 L/kg 0,5-1,5 h 
LSD  3-4 h 
Methadone 1-8 L/kg 15-55 h 
Opiates (Morphine) 3-4 L/kg 1-7 h 
Table 10. Pharmacokinetics parameters of drugs of abuse 
6. Post-analytical aspects of immunoassay in toxicology 
When the results are obtained, the staff must decide how to prepare the report. Quantitative 
blood and serum results seem to be easy interpreted. But for full interpretation the physician 
needs to know some more information, for example elimination half-life, volume of 
distribution. The pharmacokinetic parameters of some drugs of abuse are showed in Table 
10. Other data also influence the results interpretation: poisoning circumstances, 
information about the dose of ingested compound, time from exposition or ingestion to 
collecting blood or urine sample, treatment started in ambulance.  
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Drug Time to 
achieve 
steady state
Elimination half 
life 
Protein 
binding
Usual sampling 
time 
Usual 
therapeutic 
range 
Acetaminophen 5-20 h 1-4 h 20-30 % 1 h 10-20 mg/l 
Carbamazepine 2-6 days 6-25 h 65-80 % before next dose 
(Cmin) 
4-11 mg/l 
Ethosuximide 5-15 days 30-60 h (adults) 
20-56 h 
(children) 
0 % before next dose 
(Cmin) 
40-100 mg/l 
Phenobarbital 10-25 days 
(adults and 
adolescents)
8-20 days 
(infants and 
children) 
50-150 h (adults)
40-130 h (infants 
and children) 
60-200 h 
(newborns) 
 
50 % before next dose 
(Cmin) 
10-40 mg/l 
Phenytoin 2-6 h 20-30 h 92 % before next dose 
(Cmin) 
10-20 mg/l 
(adults and 
children) 
6-14 mg/l 
(neonates) 
Primidone 2-4 days 4-22 h ≤ 35 % before next dose 
(Cmin) 
5-15 mg/l 
Valproic Acid 2-4 days 6-17 h (adults) 
5-15 h (infants 
and children) 
15-60 h 
(newborns) 
90 % before next dose 
(Cmin) 
50-100 mg/l 
Theophylline 2-3 days 
(adults) 
1-2 days 
(children) 
1-5 days 
(infants) 
120 h 
(newborns) 
3-12 h (adults 
non smokers) 
4 h (adults 
smokers) 
2-10 h (children)
3-14 h (infants) 
24-30 h 
(newborns) 
55-65 % 4-6 h after 
infusion 
beginning (max)
4-8 h after oral 
administration 
(Cmax) 
before infusion 
or next dose 
(Cmin) 
8-20 mg/l 
(asthma) 
6-11 mg/l 
(neonatal 
apnea) 
Digoxin 5-7 days 20-50 h (adults) 
12-24 h 
(children) 
18-33 h (infants) 
35-42 h 
(neonates) 
20 % 8-24 h after 
administration 
0,8-2,0 ng/ml 
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Drug Time to 
achieve 
steady state
Elimination half 
life 
Protein 
binding
Usual sampling 
time 
Usual 
therapeutic 
range 
Tricyclic Antidepressants
Amitryptyline 3-8 days 17-40 h 90 % 
before next dose 
(Cmin) 
120-250 ng/ml 
Clomipramine 7-14 days 19-37 h 90-98 % Up to 700 
ng/ml 
Desipramine 2,5-11 days 12-54 h 75-90 % 125-300 ng/ml 
Doxepin 9 days 8-25 h 68-85 % 150-250 ng/ml 
Imipramine 2-5 days 6-28 h 63-96 % 150-250 ng/ml 
Nortryptyline 4-20 days 18-56 h 87-93 % 50-150 ng/ml 
Trimipramine 3-8 days 16-40 h 93-97 % 70-250 ng/ml 
Antibiotics 
Amikacin 
2,5-15 h 
(adults < 30 
years) 
7,5-75 h 
(adults > 30 
years) 
2,5-12,5 h 
(children) 
10-45 h 
(neonates) 
0,5-3 h (adults < 
30 years) 
1,5-15 h (adults > 
30 years) 
0,5-2,5 h 
(children) 
2-9 h (neonates) 
≤ 10 % 
0,5-1 h after 
infusion (Cmax)
before next dose 
(Cmin) 
20-30 mg/l 
(Cmax) 
< 5 mg/l 
(Cmin) 
Gentamycin 5-10 mg/l 
(Cmax) 
< 2 mg/l 
(Cmin) 
Netilmicin 5-12 mg/l 
(Cmax) 
< 3 mg/l 
(Cmin) 
Tobramycin 5-10 mg/l 
(Cmax) 
< 2 mg/l 
(Cmin) 
Streptomycin 10-15 h 2-3 h 30 % 1-2 h after IM 
dose (Cmax) 
before next dose 
(Cmin) 
15-40 mg/l 
(Cmax) 
< 5 mg/l 
(Cmin) 
Vancomycin 20-30 h 4-10 h (adults) 
2-3 h (children) 
6-10 h (neonates)
30-55 % 1 h after 
infusion (Cmax)
before next dose 
(Cmin) 
20-40 mg/l 
(Cmax) 
5-10 mg/l 
(Cmin) 
Table 11. Pharmacokinetics parameters and chosen information about drugs determined for 
TDM purposes 
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Positive result usually means, that the patient ingested the determined substance. But 
positive result can be also generated by interfering compounds. The interferences are 
described in chapter about immunoassay tests specificity. When the time from substance 
ingestion and collecting blood sample is too short (shorter than time, when maximum blood 
concentration is observed), the determination should be performed once again. The second 
sampling time should be set correct, in order to reflect the tissues concentration. For 
example after digoxin ingestion the drug is distributed to muscle tissues and the time of 
setting equilibrium between serum and tissues is 6-8 h. Blood digoxin concentration 
measured earlier does not correlate the medical symptoms and severity of poisoning. 
Negative result usually means, that the patient didn’t ingest the determined substance. But 
negative result are obtained when the sample is collected in wrong time, too early or too late 
(out of the detection window). Negative result is obtained, when the method is not sensitive 
enough or cut-off concentration is too high. The next reason of negative result is limited 
sensitivity of the test for the measured analyte, when the immunoassay is dedicated for the 
group of substances. For example diazepam and nordiazepam are detected in 
benzodiazepine immunotests in low concentration. But lorazepam and chlordiazepoxide are 
detected in benzodiazepine test in high concentration, sometimes three or four times higher 
than diazepam. The implication of that can be false negative result, despite drug ingestion 
and observed poisoning symptoms. 
So the result report should contain not only the determination result but information about 
assay method, its sensitivity (limit of detection, cut-off value), specificity (some most 
important interfering compounds) and recommendation for confirmation of the result. 
7. Summary 
Immunoassay methods are commonly used in laboratories. Toxicologists use them as useful 
screening in medical diagnosis of acute poisoning, checking abstinence, forensic purposes 
and therapeutic drug monitoring. When short time of analysis is important, immunoassay is 
the best method. 
Despite many positive points, the method has some disadvantages. Commonness and low 
costs encourage performing the assays by unqualified staff. Forensic toxicologists always 
perform results confirmation. In medical laboratories the confirmation is not obligatory, and 
usually is not necessary, when interpretation is made in correlation to patient’s condition.  
Reporting rapid test result is sometimes dicey, there is a risk of false result. That is why the 
result report must contain information about the immunological methods used to perform 
determination, it’s sensitivity, specificity and possible interferences. 
This would keep confidence in laboratory results. 
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